Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Becton Dickinson and Co (BDX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Becton Dickinson and CoTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Becton Dickinson and Co vs Inovio Pharmaceuticals Inc — how do they compare? Becton Dickinson and Co trades at $179.16 (market cap $49.41B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Becton Dickinson and Co is far larger — about 629× Inovio Pharmaceuticals Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

BDXINO
Market Cap
$49.41B$78.55M
Sector
HealthHealth
52-Week High
$185.39$2.87
52-Week Low
$138.62$0.66
Enterprise Value
$65.51B$49.56M
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Becton Dickinson and Co

BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.

The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO